The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Sequencing bispecific antibodies and CAR-T in multiple myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the sequencing of bispecific antibodies and CAR T-cell therapy in multiple myeloma (MM), highlighting the importance of considering antigen loss and T-cell function. Dr Popat notes that salvage therapy with bispecifics following CAR T-cell therapy is often feasible; however, the reverse approach can be problematic as bispecific antibody treatment may impair T-cell fitness. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
